Concurrent chemo-radiotherapy with mitomycinc (MC) compared to porfiromycin (PO) in squamous cell carcinoma of the head and neck (SCCHN): final results of a randomized clinical trial

Abstract

Purpose/Objective: Previous randomized trials have shown a benefit with concurrent use of the hypoxic cell cytotoxin MitomycinC (MC) and radiation (RT) in the management of SCCHN. Based on laboratory data demonstrating superior hypoxic cell cytotoxicity with Porfiromycin (PO, Methyl-mitomycinC), and a Phase I trial demonstrating acceptable toxicity with concurrent RT and PO at 40mg/M2, we conducted a randomized trial comparing MC to PO in combination with RT in the management of SCCHN.